BCL2L11 and lung carcinoma: Notably, CRL5 has been implicated in mediating resistance to CDK9 and MCL1 inhibitors in lung cancer cells by targeting pro‐apoptotic proteins NOXA and BIM for degradation.[60] Our findings extend this role by showing that CUL5 also promotes resistance to the anti‐microtubule agent paclitaxel, which stabilizes microtubules, by delaying mitotic exit.